Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small molecule not a peptide that has gained attention for its novel metabolic mechanism
Until then, keep vials in their lyophilized powder form, stored in the freezer and away from light
If youre ever unsure about technique or dosing, your care team is available to help
This multi-receptor approach distinguishes it from existing licensed medicines such as semaglutide (Ozempic, Wegovy) or tirzepatide licensed in the UK as Mounjaro for type 2 diabetes and as Zepbound for obesity which act on fewer receptor pathways
Trop J Pharm Res 2024;23(2):379386